Program
venglustat
Also written as “Venglustat”, “Venglustat (GZ402671)” and “GZ/SAR402671”.
In Sanofi's pipeline, Oral GCS inhibitor
. Its studies are mostly in Fabry Disease · Gaucher Disease · Polycystic Kidney, Autosomal Dominant · Tay-Sachs Disease · Liver Diseases, led by Sanofi.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 195 open or running | phase 3since May 1, 2018 | Aug 24, 2012 | Jan 14, 2030phase 3 · NCT07927140 |
- Named in Sanofi’s own pipeline as
venglustat
, phase 4, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Aug 24, 2012.
- Jun 30, 2015Phase 2 study in Fabry DiseaseNCT02489344 · 8 enrolled · United States, France, Poland and more
- Jul 20, 2016Phase 2 study in Gaucher DiseaseNCT02843035 · 12 enrolled · United States, Germany, Japan and more
- Sep 14, 2016Phase 2 study in Parkinson DiseaseNCT02906020 · 273 enrolled · United States, Austria, Canada and more
- May 1, 2018Phase 3 study in Polycystic Kidney, Autosomal DominantNCT03523728 · 478 enrolled · United States, Argentina, Australia and more
- Sep 26, 2018Phase 1 study in Polycystic Kidney, Autosomal DominantNCT03687554 · 24 enrolled · United States
- Jan 6, 2020Phase 3 study in Tay-Sachs DiseaseNCT04221451 · 75 enrolled · United States, Argentina, Brazil and more
- Jan 8, 2021Phase 3 study in Kidney Diseases, CysticNCT04705051 · 24 enrolled · United States, Australia, Belgium and more
- Oct 20, 2021Phase 3 study in Fabry DiseaseNCT05206773 · 122 enrolled · United States, Argentina, Australia and more
- Jan 20, 2022Phase 3 study in Gaucher DiseaseNCT05222906 · 43 enrolled · United States, Argentina, Canada and more
- Feb 3, 2022Phase 1 study in Disorders of Sphingolipid MetabolismNCT05238714 · 6 enrolled · United Kingdom
- Mar 4, 2022Phase 3 study in Fabry DiseaseNCT05280548 · 104 enrolled · United States, Austria, Canada and more
- Jan 30, 2023Phase 1 study in Liver DiseasesNCT05718258 · 26 enrolled · United States, Germany
- May 13, 20243 phase 1 studies in Healthy VolunteersNCT06421714, NCT06418620, NCT06418607
- Jun 24, 2026Phase 3 study in Gaucher DiseaseNCT07927140 · 18 planned
Ahead
- Jan 14, 2030Primary completion: phase 3 study in Gaucher DiseaseNCT07927140
TargetBeta
“Oral GCS inhibitor”the company's pipeline, read by Claude · source
“Ceramide glucosyltransferase inhibitor”ChEMBL 37, by rule
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07927140Gaucher Disease | 3 | Not yet recruiting | Jan 14, 2030 | 18 |
| NCT06421714Healthy Volunteers · United States | 1 | Completed | Oct 14, 2018 | 8 |
| NCT06418620Healthy Volunteers · United States | 1 | Completed | Aug 7, 2020 | 9 |
| NCT06418607Healthy Volunteers · United States | 1 | Completed | Jul 13, 2020 | 65 |
| NCT05718258Liver Diseases · United States, Germany | 1 | Completed | Jan 29, 2024 | 26 |
| NCT05280548Fabry Disease · United States, Austria, Canada and more | 3 | Active, not recruiting | May 22, 2026 | 104 |
| NCT05238714Disorders of Sphingolipid Metabolism · United Kingdom | 1 | Completed | Jun 26, 2020 | 6 |
| NCT05222906Gaucher Disease · United States, Argentina, Canada and more | 3 | Active, not recruiting | Oct 2, 2025 | 43 |
| NCT05206773Fabry Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 17, 2025 | 122 |
| NCT04705051Kidney Diseases, Cystic · United States, Australia, Belgium and more | 3 | Terminated | Jul 13, 2021 | 24 |
| NCT04221451Tay-Sachs Disease · United States, Argentina, Brazil and more | 3 | Terminated | Dec 26, 2024 | 75 |
| NCT03687554Polycystic Kidney, Autosomal Dominant · United States | 1 | Completed | Feb 27, 2019 | 24 |
| NCT03523728Polycystic Kidney, Autosomal Dominant · United States, Argentina, Australia and more | 3 | Terminated | Aug 3, 2021 | 478 |
| NCT02906020Parkinson Disease · United States, Austria, Canada and more | 2 | Terminated | Dec 18, 2020 | 273 |
| NCT02843035Gaucher Disease · United States, Germany, Japan and more | 2 | Active, not recruiting | Oct 30, 2026 | 12 |
| NCT02489344Fabry Disease · United States, France, Poland and more | 2 | Completed | Nov 20, 2018 | 8 |
| NCT02228460Fabry Disease · United States, France, Poland and more | 2 | Completed | Sep 2016 | 11 |
| NCT01710826Healthy · United States | 1 | Completed | Feb 2013 | 36 |
| NCT01674036Healthy Volunteer · United States | 1 | Completed | Jan 2013 | 63 |
How it is read
Names in the registry
- “Venglustat”, 7 entries
- “Venglustat (GZ402671)”, 3 entries
- “GZ/SAR402671”, 2 entries
- “Genz-682452”, 2 entries
- “venglustat (GZ402671)”, 1 entry
Codes read as this program: SAR402671.
Conditions, from the studies’ own filings
- Fabry Disease, 4 studies
- Gaucher Disease, 3 studies
- Polycystic Kidney, Autosomal Dominant, 2 studies
- Tay-Sachs Disease, 1 study
- Liver Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.